Tag Archives: public policy

Corporate-Sponsored University Research Valuable for Further Innovation

SBIR Reauthorization Moves Forward

New research published in Nature, Technology Transfer: Industry-funded academic inventions boost innovation, provides data undermining “assumptions that corporate-funded academic research is less accessible and useful to others.” After reviewing empirical evidence covering 20 years of inventions in the University of California system the authors find that: “Corporate-sponsored research is surprisingly valuable for further innovation. Data collected over 20 years at nine campuses and three national laboratories administered by the University of California show that corporate-sponsored Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

PA Bio Names State Official of the Year

admin-ajax (1)

Pennsylvania State Representative Warren Kampf was selected as the recipient Pennsylvania Bio’s 2013 State Official of the Year Award. Representative Kampf will be honored at Pennsylvania Bio’s Annual Dinner and Awards Celebration on March 12th at the Pennsylvania Convention Center in Philadelphia.  The State Official of the Year recognizes a public official from the Commonwealth of Pennsylvania who has distinguished him/herself as a leader in the bioscience industry. The honoree is selected by the Pennsylvania Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

A New Addition to Pennsylvania Bio’s Leadership Team

ct-115x76

To effectively achieve our mission as the champion and advocate of biotechnology, BIO works with a broad network of organizations. Foremost among these relationships are the ones we possess with a broad network of state-based organizations known as the Council of State Bioscience Associations (CSBA). Pennsylvania Bio (PA Bio) has been a key ally to BIO and vocal advocate for state and federal public policy in support of the biotechnology industry since our inception. Just Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

FDA Check-Up: Drug Development and Manufacturing Challenges

Paul Hastings

I have over 27 years of experience in the biotechnology and pharmaceutical industry. My current company, OncoMed Pharmaceuticals, is working at the cutting edge of oncology research, focused on antibodies that target a specific set of cells within tumors, known as tumor initiating cells, that drive the growth of the tumor and can differentiate into various cell types within the tumor. Currently, we have five products in clinical development in over 13 completed or ongoing Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Innovation Act Passed By House

House

The Innovation Act (H.R. 3309), which is intended to reduce frivolous patent-related litigation, was passed by the House today. As we’ve noted, BIO does not support the bill in its current form, which would ultimately undermine biotech research and innovation by making it more difficult for patent holders with legitimate claims to protect their intellectual property. A number of Representatives offered amendments to the bill, several of which BIO supported. These amendments address serious shortcomings with the bill, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,